Who actually oversees the pharmacy that made your vial

The sentence that settles the licensing question

The agency published a page addressed to telehealth companies promoting compounded drugs. It lists claims it considers false or misleading, and one entry answers a question this market asks constantly.

A company should not be claiming that a compounded drug is sourced from an approved or licensed pharmacy or outsourcing facility, because, in the agency's own words, it "does not approve or license any facility."

That is a flat statement about federal authority. Approval attaches to products, and it does not attach to compounded ones. Licensing attaches to facilities, and it is not something the federal agency does.

The same list names a second habit worth recognizing. It warns against branding on a website that falsely or misleadingly implies the telehealth company is itself the compounder.

Who does the day-to-day work

The agency is equally direct about the division of labor, on a page written for state officials rather than for buyers.

States, it says, "are primarily responsible for day-to-day oversight over the vast majority of the thousands of compounders in the U.S., most of which do not register with FDA."

Read the second half of that sentence carefully. Most compounders are not on any federal register, and that is the ordinary condition of the category rather than a warning sign about a particular business.

The page also says state officials are often the first to identify compounders operating like conventional manufacturers, or engaging in production practices that could lead to patient harm. The regulator closest to the building is the one most likely to notice.

Where a federal license does appear, it is a state one

The federal compounding provision does not create a federal pharmacy license. It borrows the state one.

Its exemption applies where compounding is done by a licensed pharmacist in a state licensed pharmacy or a federal facility, or by a licensed physician. The order has to be written by a licensed practitioner authorized by state law to prescribe.

So a state license is not a lesser credential sitting underneath a federal one. It is the condition the federal text is written on top of, which is why a pharmacy name is worth more to a reader than a federal-sounding phrase.

The second compounding category makes the same point from the other end. Its closing subsection says paying the federal fee does not relieve a facility licensed as a pharmacy in a state of its obligation to pay that state's pharmacy licensing fees.

What federal inspection authority over a pharmacy really is

It is often said that the federal agency cannot inspect a pharmacy. The inspection section says something narrower and more conditional.

The paragraph granting the power runs to several sentences. One of them extends an inspection of a drug establishment to "all things therein (including records, files, papers, processes, controls, and facilities)" bearing on whether products are adulterated or misbranded. The exception that follows is written against a single numbered sentence of that paragraph, not against the section.

And it reaches only pharmacies that satisfy three conditions at once. They maintain establishments "in conformance with any applicable local laws regulating the practice of pharmacy and medicine." They are regularly engaged in dispensing prescription drugs on prescriptions of practitioners licensed to administer them. And they do not "manufacture, prepare, propagate, compound, or process drugs or devices for sale other than in the regular course of their business of dispensing or selling drugs or devices at retail."

That third condition is the load-bearing one for this market. A business whose compounding has outgrown ordinary retail dispensing is describing itself out of the carve-out, and the outsourcing facility section removes the same carve-out by name for anyone who registers.

What happens at a state line

A compounded preparation that crosses a state line raises a question the statute answers with an unusual pair of alternatives.

The statute offers two branches. Compounding qualifies for the exemption if it happens in a state that has entered into a memorandum of understanding with the agency. That memorandum addresses interstate distribution of inordinate amounts of compounded drug products, and complaint investigation. Where a state has not entered into one, a limit applies instead. Out-of-state distribution must stay "in quantities that do not exceed 5 percent of the total prescription orders dispensed or distributed by such pharmacy or physician."

The agency's own page on state collaboration records what happened next. A standard memorandum was made available for signature in October 2020, developed in consultation with the national association of state pharmacy boards. Several compounding pharmacies sued. In September 2021 a federal district court remanded the standard memorandum to the agency, and the agency has said it intends to address the statutory provisions on these distributions through notice-and-comment rulemaking.

So the limit is written in the statute and the instrument that switches between its two branches has an unsettled history. Nothing here should be read as a claim about how the provision is enforced today, or about any pharmacy's compliance with it.

The information does move between the two regulators

The two layers are not sealed off from each other, and the routes are published.

Under the legislation that created the outsourcing facility category, the agency may receive submissions from state boards of pharmacy. Those cover certain actions taken against compounding pharmacies, or concerns that a pharmacy may be acting contrary to the compounding provision. The same law requires the agency to notify state boards when it receives such submissions or makes such a determination.

The agency also describes sharing inspection findings, complaints and adverse event information with states, inviting states to join inspections of compounders, and holding an annual meeting with state compounding regulators.

For a reader, the practical consequence is that a complaint filed with a state board is not a dead end, and neither is one filed federally. Where a report about a product goes is covered separately on this site.

The slogan that does not have the statute behind it

There is a sentence repeated across this industry: that the federal agency does not regulate the practice of medicine. It is usually attached to a specific section of the Act.

That section exists, and it is titled "Practice of medicine." Its operative words are that nothing in the chapter shall be construed to limit or interfere with a practitioner's authority "to prescribe or administer any legally marketed device to a patient." The sentence ends by requiring that this happen within a legitimate practitioner-patient relationship.

The noun is device. The section's two remaining sentences are about devices as well, preserving the agency's authority over device labeling and distribution restrictions and over promotion of unapproved device uses.

The relationship between federal drug authority and state practice regulation is real, and this article describes it from the compounding provisions, which say so directly. It is not supported by that section, and a page that cites it for a claim about a drug is citing something that does not say it.

What to do with all of this

Three questions come out of it, and all three are answerable before buying anything.

Which state licensed the facility that makes the preparation, which requires knowing the facility's name. Whether that facility has also registered federally as an outsourcing facility, which is a public list rather than a claim. And whether the seller is describing a federal standing it cannot have, such as an approved or licensed facility.

The last of those is the one the agency wrote down for this exact audience. A page claiming an approved or licensed pharmacy is claiming something no facility holds.

None of these questions is about whether a compound works. They are about who would find out if something went wrong, and how quickly.

Sources

Each document below is named as it names itself, with the date printed on that document rather than the day it was read.

1. FDA to Telehealth Companies: What to Know When Promoting Compounded Drugs, listing claims the agency considers false or misleading and stating that FDA does not approve or license any facility — U.S. Food and Drug Administration, June 2026
2. Compounding Information for States, describing state responsibility for day-to-day oversight, the standard memorandum of understanding on interstate distribution and its litigation history, and the two-way notification duties under section 105 of the Drug Quality and Security Act — U.S. Food and Drug Administration, August 2026
3. Title 21 United States Code section 374, Inspection, including the paragraph (a)(2)(A) exception for pharmacies and its three conditions — Office of the Law Revision Counsel, U.S. House of Representatives, September 2026
4. Title 21 United States Code section 396, Practice of medicine, whose operative sentence protects a practitioner's authority to prescribe or administer any legally marketed device — Office of the Law Revision Counsel, U.S. House of Representatives, September 2026
5. Title 21 United States Code section 353a, Pharmacy compounding, including subsection (b)(3)(B) on the memorandum of understanding and the 5 percent limit on out-of-state distribution — Office of the Law Revision Counsel, U.S. House of Representatives, September 2026